

1 **Title:** Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and
2 other variants in paired samples after two or three doses of mRNA vaccine

3

4

5 Amanda K. Debes, PhD, MS¹

6 Shaoming Xiao, MSPH²

7 Emily R. Egbert MPH, MAT²

8 Patrizio Caturegli MD, MPH²

9 Ioannis Sitaras, PhD, MRes¹

10 Andrew Pekosz, PhD^{1,2}

11 Aaron M. Milstone, MD, MHS^{1,2}

12 ¹ Johns Hopkins University Bloomberg School of Public Health , Baltimore, MD, USA

13 ² Johns Hopkins University School of Medicine , Baltimore, MD, USA

14 **Correspondence:**

15

16 Amanda K. Debes PhD, MS

17 Department of International Health

18 615 N. Wolfe Street, E5036

19 Baltimore, MD 21205

20 adebes1@jhu.edu

21

22 **Manuscript Word Count:** 594

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41 **Abstract**

42 Recognizing that anti-SARS-CoV-2 antibody levels wane over time following the 2-dose
43 SARS-CoV-2 mRNA series, the FDA approved a booster dose for people greater than 12 years
44 old. Limited data exist on whether a booster dose of the mRNA vaccine results in greater
45 antibody protection than the primary series. We examined total and neutralizing antibodies to
46 the spike protein of SARS-CoV-2, and neutralizing antibodies against Washington-1 (WA-1) and
47 variants of concern (VOCs) including Beta, Delta and Omicron in a longitudinal cohort.
48 Healthcare workers (HWs) were included in the analysis if serum was collected 1) within 14-44
49 days post-dose2 of an mRNA SARS-CoV-2 vaccine (Timepoint 1, TP1), or 2) at least 8 months
50 post-dose2 (Timepoint 2, TP2), or 3) within 14-44 days following mRNA booster (Timepoint 3,
51 TP3). HWs with prior covid-positive PCR were excluded. We found that there is little to no
52 neutralizing capability following a 2-dose mRNA vaccine series against the omicron variant, and
53 neutralizing capacity to any variant strain tested has been lost by 8-months post two-dose
54 vaccination series. However, the mRNA booster series eliminates the immune escape observed
55 by the omicron variant with the two-dose series. Neutralizing titers were significantly higher for
56 all variants post-boost compared to the titers post two-dose series. The longitudinal nature of
57 our cohort facilitated the analysis of paired samples pre and post boost, showing a greater than
58 15-fold increase in neutralization against omicron post-boost in these paired samples. An mRNA
59 booster dose provides greater quantity and quality of antibodies compared to a two-dose
60 regimen and is critical to provide any protection against the omicron variant.

61

62

63

64

65

66

67 **Introduction**

68 SARS-CoV-2 antibody levels wane following two-dose mRNA vaccination and infection.¹
69 mRNA booster doses are available and protect against hospitalization and death, but booster
70 uptake remains low.² Our objective was to compare total and neutralizing SARS-CoV-2 spike
71 antibodies against against Washington-1 (WA-1) and variants of concern (VOC) in a longitudinal
72 cohort.

73 **Methods**

74 Healthcare workers (HWs) were consented into a seroprevalence cohort beginning June
75 2020 and followed through November 2021.¹ HWs provided serum samples longitudinally and
76 were included in this analysis if serum was collected 1) within 14-44 days post-dose2 of an
77 mRNA SARS-CoV-2 vaccine (Timepoint 1, TP1), or 2) at least 8 months post-dose2 (Timepoint
78 2, TP2), or 3) within 14-44 days following mRNA booster (Timepoint 3, TP3). HWs with prior
79 covid-positive PCR were excluded. To determine if the increase in magnitude of antibody
80 response to the mRNA vaccine strain, as measured by enzyme-linked immunosorbent assay
81 (ELISA) [Euroimmun], led to an increased recognition of VOCs, neutralizing antibody titer (NT)
82 assays were performed against the vaccine strain (WA-1) and the Beta, Delta and Omicron
83 variants as previously described.^{1,3} For NT assays, 45 HWs were selected, prioritizing paired
84 samples from TP1 and TP3, and others were selected at random.

85 Wilcoxon rank sum test was used for unpaired analyses, and Wilcoxon signed rank test
86 and Friedman test for paired analyses. The Johns Hopkins University Institutional Review
87 Board approved this study. Analyses were performed in R, version 4.1.2.

88 **Results**

89 Of 3032 HWs originally enrolled in the longitudinal cohort, 1353 contributed serum to at
90 least one of the 3 groups: 507 within in TP1, 879 in TP2, and 273 in TP3. Of these 1353
91 participants, 81% were women, 96% were Non-Hispanic/Latino, and 81% were White. The
92 median (IQR) age of participants was 41.8 (33.8 - 53.3) years.

93 High levels of antibodies in TP1 waned to lower levels in TP2 and then boosted to much
94 higher levels in TP3. Of the TP3 samples tested, 94% demonstrated spike IgG assay saturation
95 compared to 59% in TP1 (Figure 1). Spike IgG measurements correlated with NT against WA-1.
96 TP1 samples had lower NT activity across VOCs compared to WA-1 (Figure 2). By TP2, there
97 was little NT to Beta and Delta, and none to omicron (titer<20).⁴ At TP3, NT activity against all
98 viruses was boosted and the fold reductions between WA-1 and VOCs were less than those
99 observed in TP1 among paired samples.

100 101 **Discussion**

102 After two-dose vaccination, HWs developed high spike IgG and NT to vaccine strains but
103 significantly lower NT against VOC was evident. By 8-month post-dose-2, all antibody
104 measures had waned and NT against VOC had dropped to nearly undetectable levels. Boosting
105 proved critical, as NT were significantly higher for all VOC compared to post-dose2 titers,
106 including a >15 fold increase in neutralization against omicron in paired samples.

107 Limitations include that paired serum was only available post-dose2 and post-boost, and
108 nABs titers were only performed on a small subset. The corresponding antibody trends between
109 serum IgG and NT supports that despite only testing a subset of the participants for virus
110 neutralization, all participants likely had robust broad NT post-boost, findings supported by
111 recently published pre and post-boost studies.⁵

112 This study demonstrates that in paired samples an mRNA vaccine booster produces
113 greater quantity and function of spike antibodies and NT as compared to primary SARS-CoV-2
114 mRNA immunization and was necessary to restore measurable NT to VOC. The booster dose
115 eliminated the immune escape observed by Omicron following two-dose mRNA immunization.
116 The variable NT to mRNA booster and whether breakthrough omicron infection boosts NT must
117 be investigated to understand durable immunity against future VOC.

118

119 **Acknowledgements:** The authors would like to thank members of the Johns Hopkins Hospital
120 Clinical Immunology Laboratory, Danielle Koontz and Ani Voskertchian of the Johns Hopkins
121 Division of Pediatric Infectious Diseases, Elizabeth Colantuoni from the Johns Hopkins
122 Bloomberg School of Public Health, and Avinash Gadala from the Johns Hopkins Health
123 System. Research reported in this publication was supported in part by the National Institute of
124 Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award number
125 K24AI141580 (A.M.), the Johns Hopkins Center of Excellence in Influenza Research and
126 Surveillance (NIH/NIAID N2772201400007C AP) and the generosity of the collective community
127 of donors to the Johns Hopkins University School of Medicine and the Johns Hopkins Health
128 System for Covid-19 research.

129

130 **Conflict of Interest Disclosure:** A.M. reports grant support from Merck for work unrelated to
131 this study. Other authors report no conflicts.

132

133

134

135

136

137

138

139

140

141

142 **References**

143 1. Zhong D, Xiao S, Debes AK, et al. Durability of Antibody Levels After Vaccination With mRNA
144 SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection. *Jama*. 2021.

- 145 2. Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness
146 Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and
147 Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance -
148 Nine States, June-August 2021. *MMWR Morbidity and mortality weekly report*. 2021;70(37):1291-
149 1293.
- 150 3. Karaba AH, Zhu X, Liang T, et al. A third dose of SARS-CoV-2 vaccine increases neutralizing
151 antibodies against variants of concern in solid organ transplant recipients. *Am J Transplant*. 2021.
- 152 4. Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a
153 COVID-19 convalescent plasma donor population. *The Journal of clinical investigation*.
154 2020;130(11):6141-6150.
- 155 5. Wu M, Wall EC, Carr EJ, et al. Three-dose vaccination elicits neutralising antibodies against
156 omicron. *The Lancet*. 2022.

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175 Figure 1: Spike IgG serum antibodies and live-virus neutralizing antibody titers (NT) against the
176 vaccine strain (WA-1). Data shown at threetime points: within 14-44 days post-dose2 (Timepoint

177 1), at least 8 months post-dose2 (Timepoint 2), and within 14-44 post-booster (Timepoint 3). IgG
178 antibody measurements estimated optical density ratios with a lower threshold of 1.23 and
179 upper threshold of 11.00 based on assay saturation. NTs were reported using NT50, and a
180 positive threshold was defined as $NT \geq 20$.⁴ Timepoint 1: 396(78%) females, 484(95%) non-
181 Hispanic/Latino, 383(76%) got Pfizer for primary dose, 395 (78%) whites, median age(IQR):
182 39.9(32.4, 51.9) Timepoint 2: 739(84%) females, 845(96%) non-Hispanic/Latino, 657(75%) got
183 Pfizer for primary dose, 723 (82%) whites, median age(IQR): 43.0(35.1, 53.5) Timepoint 3:
184 215(79%) females, 263(96%) non-Hispanic/Latino, 225(82%) got Pfizer for primary dose, 238
185 (87%) whites, median age(IQR): 44.9(34.3, 55.6). NT were performed at Timepoint 1 (n=15),
186 Timepoint 2 (n=14), Timepoint 3 (n=16).

187

188

189

190

191

192

193

194

195

196

197

198

199

200 Figure 2: Comparison of neutralizing antibody titers (NT) to SARS-CoV-2 vaccine strain (WA-1),
201 Beta, Delta, and Omicron VOCs from healthcare workers with paired serum samples in a
202 longitudinal cohort. Data shown at three timepoints: within 14-44 days post-dose-2 (Timepoint

203 1), at least 8 months post-dose-2 (Timepoint 2), and within 14-44 post-booster (Timepoint 3).
204 Top panel shows NT titer for each variant across the three timepoints with connecting lines
205 illustrating 15 paired samples in Timepoints 1 and 3. Bottom panel shows NT at each timepoint
206 for each VOC. Fold change (increase/difference) represents geometric median fold change. P-
207 values have been corrected for multiple comparisons using Bonferroni methods.



